Replicel Life Sciences Stock Today
| REPCF Stock | USD 0 0.0009 90.00% |
Performance13 of 100
| Odds Of DistressLess than 9
|
RepliCel Life is trading at 0.0019 as of the 1st of February 2025. This is a 90.00 percent increase since the beginning of the trading day. The stock's lowest day price was 0.0019. RepliCel Life has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 5th of August 2024 and ending today, the 1st of February 2025. Click here to learn more.
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada. Replicel Life operates under Biotechnology classification in the United States and is traded on OTC Exchange.. The company has 54.36 M outstanding shares. More on RepliCel Life Sciences
Moving against RepliCel Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
RepliCel Pink Sheet Highlights
| Business Concentration | Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) |
RepliCel Life Sciences [REPCF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate RepliCel Life's market, we take the total number of its shares issued and multiply it by RepliCel Life's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. RepliCel Life Sciences classifies itself under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 54.36 M outstanding shares.
RepliCel Life Sciences has accumulated about 228 K in cash with (2.51 M) of positive cash flow from operations.
Check RepliCel Life Probability Of Bankruptcy
Ownership AllocationRepliCel Life owns a total of 54.36 Million outstanding shares. RepliCel Life holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 68.42 pct. of RepliCel Life Sciences outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check RepliCel Ownership Details
RepliCel Life Sciences Risk Profiles
| Mean Deviation | 75.82 | |||
| Semi Deviation | 21.57 | |||
| Standard Deviation | 173.52 | |||
| Variance | 30109.03 |
RepliCel Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in RepliCel Life without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
RepliCel Life Corporate Management
| BA CPA | Chief Officer | Profile | |
| Kevin McElwee | Chief Scientific Officer | Profile | |
| MSc PMP | Clinical Consultant | Profile | |
| Ben Austring | Chief Mang | Profile | |
| Andrew Schutte | CEO Pres | Profile | |
| BEd LLB | Corp Director | Profile | |
| Rolf MD | Chief Board | Profile |
Other Information on Investing in RepliCel Pink Sheet
RepliCel Life financial ratios help investors to determine whether RepliCel Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RepliCel with respect to the benefits of owning RepliCel Life security.